Overview

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Status:
Completed
Trial end date:
2019-11-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Celgene
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Necitumumab
Paclitaxel